Long term follow up data from a large international phase III trial shows that postmenopausal women with early stage hormone receptor positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane Aromasin for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years <a href=
https://buycialis.sbs>cialis vs viagra</a>
